GlassScriptPhysician profile
Karlee Wagoner
NPI 1043311632
$5,080.46
in general payments reported to CMS, 2019-2025
26 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $786 · 2023: $1,250 · 2024: $1,498 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Education: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.77 |
| Education | $430.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $620.81 | 2022-2025 | Sotyktu |
| Abbvie INC. | $547.09 | 2021-2025 | |
| Genzyme Corporation | $493.29 | 2021-2025 | |
| Galderma Laboratories, L.P. | $367.50 | 2021-2025 | Nemluvio, Dysport, Aklief |
| Regeneron Healthcare Solutions, INC. | $351.23 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $312.73 | 2022-2025 | Taltz, Ebglyss |
| Amgen INC. | $278.17 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $262.99 | 2022-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $258.98 | 2023-2025 | |
| Janssen Biotech, INC. | $250.06 | 2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $207.76 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $204.58 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $184.84 | 2023-2025 | Zoryve |
| Revance Therapeutics, INC. | $160.50 | 2024-2025 | Daxxify |
| Leo Pharma INC. | $131.29 | 2021-2025 | Adbry |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.42 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $85.78 | 2021-2023 | Winlevi, Absorica Ld |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $66.44 | 2022-2025 | Cabtreo |
| Verrica Pharmaceuticals INC. | $60.77 | 2023-2024 | Ycanth |
| Almirall LLC | $41.35 | 2021-2022 | |
| Journey Medical Corporation | $31.59 | 2022-2023 | |
| Vyne Pharmaceuticals INC. | $20.41 | 2021 | |
| Allergan, INC. | $18.52 | 2022 | |
| Epi Health, LLC | $13.07 | 2021 | |
| Genentech USA, INC. | $12.87 | 2023 | Erivedge |
| Organon LLC | $5.42 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karlee Wagoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.